Group 1 - Phathom Pharmaceuticals, Inc. announced a public offering of 6,875,000 shares of common stock priced at $16.00 per share, along with pre-funded warrants for 1,250,078 shares priced at $15.999 each, aiming for gross proceeds of approximately $130 million before expenses [1][2] - The offering is expected to close on or about January 9, 2026, pending customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 1,218,761 shares at the public offering price [1] Group 2 - The net proceeds from the offering will be used for general corporate purposes, including working capital and expenses related to commercialization and research and development [2] - Guggenheim Securities and Cantor are acting as joint bookrunning managers, with Raymond James, Needham & Company, H.C. Wainwright & Co., and Craig-Hallum serving as co-managers for the offering [2] Group 3 - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases, including the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker [5] - Vonoprazan is marketed in the U.S. under the brand name VOQUEZNA® for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

Core Points - Phathom Pharmaceuticals, Inc. will host a live webcast on October 30, 2025, at 8:00 am EDT to report its third quarter 2025 financial results and provide a business update [1] - The webcast will be accessible through the Events & Presentations section of the Phathom website, with a recording available for 90 days post-call [2] Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada [3] - Phathom markets vonoprazan in the U.S. as VOQUEZNA® for various gastrointestinal conditions, including heartburn relief and H. pylori infection treatment [3]

Core Insights - The FDA has updated the Orange Book to confirm that VOQUEZNA® (vonoprazan) is entitled to a full 10-year period of non-patent New Chemical Entity (NCE) exclusivity, extending through May 3, 2032, which supports the long-term commercial potential of the product [1][2] Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, with a key product being vonoprazan, marketed as VOQUEZNA® for various GI conditions [3] - VOQUEZNA® is a first-in-class potassium-competitive acid blocker (PCAB) used for the relief of heartburn associated with Non-Erosive GERD and for the treatment of H. pylori infection in adults [3]

Core Insights - Phathom Pharmaceuticals has appointed Ted Schroeder to its Board of Directors, which is seen as a strategic move during a critical time for the company [1][3]. Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, including the first-in-class potassium-competitive acid blocker (PCAB) vonoprazan, marketed as VOQUEZNA® [7]. Leadership Experience - Ted Schroeder brings over 30 years of experience in the biopharmaceutical industry, having held leadership roles in various companies and successfully guiding them through significant milestones and transactions [2][4]. - His previous roles include CEO of Nabriva Therapeutics and co-founder of Cadence Pharmaceuticals, which was acquired for $1.4 billion [4]. Strategic Importance - The appointment of Schroeder is expected to enhance Phathom's operational and commercial capabilities, particularly as the company aims to accelerate its commercial momentum and deliver innovative therapies to patients [3][5].

Core Viewpoint - Phathom Pharmaceuticals has appointed Steven Basta as the new President and CEO, succeeding Terrie Curran, to lead the company during a critical growth phase focused on expanding the commercial potential of its gastrointestinal treatments, particularly VOQUEZNA [1][2]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases, with a focus on the potassium-competitive acid blocker, vonoprazan, marketed as VOQUEZNA [5]. Leadership Transition - Steven Basta brings over 25 years of experience in the biopharmaceutical and medical device industries, having previously served as CEO at various companies, including SaNOtize and Mahana Therapeutics [3][4]. - Terrie Curran, the former CEO, expressed pride in the company's achievements over the past five years and confidence in its future growth potential [2]. Strategic Focus - The Board of Directors aims to accelerate commercial growth and enhance shareholder value under Basta's leadership, leveraging his extensive experience in product development and commercial strategy [2][3]. - Basta emphasized the need for innovative treatment options in the gastrointestinal market and Phathom's unique position to capture significant opportunities [2].